Catalyst Pharmaceuticals (CPRX) Stock Forecast, Price Target & Predictions
CPRX Stock Forecast
Catalyst Pharmaceuticals stock forecast is as follows: an average price target of $19.38 (represents a -9.40% downside from CPRX’s last price of $21.39) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
CPRX Price Target
The average price target for Catalyst Pharmaceuticals (CPRX) is $19.38 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $15.50. This represents a potential -9.40% downside from CPRX's last price of $21.39.
CPRX Analyst Ratings
According to 4 Wall Street analysts, Catalyst Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for CPRX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Catalyst Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 21, 2022 | - | Truist Financial | $18.00 | $19.15 | -6.01% | -15.85% |
| Dec 21, 2022 | - | H.C. Wainwright | $24.00 | $18.60 | 29.03% | 12.20% |
| Dec 19, 2022 | Joseph Catanzaro | Piper Sandler | $20.00 | $16.41 | 21.88% | -6.50% |
| Aug 24, 2022 | Scott Henry | Roth Capital | $15.50 | $14.91 | 3.96% | -27.54% |
| Aug 11, 2022 | - | Truist Financial | $17.00 | $13.46 | 26.30% | -20.52% |
| Aug 11, 2022 | - | H.C. Wainwright | $18.00 | $13.13 | 37.09% | -15.85% |
The latest Catalyst Pharmaceuticals stock forecast, released on Dec 21, 2022 by Truist Financial company, set a price target of $18.00, which represents a -6.01% decrease from the stock price at the time of the forecast ($19.15), and a -15.85% decrease from CPRX last price ($21.39).
Catalyst Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $21.39 | $21.39 | $21.39 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Catalyst Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Catalyst Pharmaceuticals's last price of $21.39. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 12, 2024 | Oppenheimer | Buy | Buy | Hold |
| Aug 12, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Aug 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2024 | Citigroup | Buy | Buy | Hold |
| Jun 03, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jun 03, 2024 | Oppenheimer | Buy | Buy | Hold |
| May 10, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| May 10, 2024 | Oppenheimer | Buy | Buy | Hold |
| May 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 27, 2024 | Citigroup | Underperform | Underperform | Hold |
Catalyst Pharmaceuticals's last stock rating was published by Oppenheimer on Aug 12, 2024. The company gave CPRX a "Buy" rating, the same as its previous rate.
Catalyst Pharmaceuticals Financial Forecast
Catalyst Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $110.57M | $102.69M | $99.58M | $85.37M | $60.76M | $57.24M | $53.11M | $43.09M | $38.31M | $35.95M | $36.37M | $30.20M | $31.01M | $29.32M | $29.60M | $29.14M | $30.12M | $30.90M | $28.84M | $12.45M |
| Avg Forecast | $150.24M | $142.46M | $141.23M | $128.38M | $133.68M | $123.41M | $111.77M | $98.78M | $105.93M | $100.37M | $91.71M | $81.62M | $58.10M | $53.69M | $49.21M | $42.75M | $38.18M | $34.59M | $31.51M | $31.68M | $30.11M | $31.50M | $29.48M | $31.46M | $29.40M | $33.19M | $18.49M | $1.61M |
| High Forecast | $156.29M | $148.20M | $146.93M | $137.01M | $136.79M | $123.43M | $111.77M | $98.78M | $107.55M | $100.38M | $95.41M | $84.91M | $60.44M | $53.69M | $49.21M | $42.75M | $38.18M | $34.59M | $31.51M | $31.68M | $30.11M | $31.50M | $29.48M | $31.46M | $29.40M | $33.19M | $18.49M | $1.61M |
| Low Forecast | $144.07M | $136.61M | $135.44M | $123.16M | $129.30M | $123.39M | $111.77M | $98.78M | $104.94M | $100.36M | $87.95M | $78.27M | $55.71M | $53.69M | $49.21M | $42.75M | $38.18M | $34.59M | $31.51M | $31.68M | $30.11M | $31.50M | $29.48M | $31.46M | $29.40M | $33.19M | $18.49M | $1.61M |
| # Analysts | 1 | 1 | 1 | 4 | 6 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | 1.04% | 1.02% | 1.09% | 1.05% | 1.05% | 1.07% | 1.08% | 1.01% | 1.00% | 1.04% | 1.15% | 0.95% | 1.03% | 0.93% | 1.00% | 0.93% | 1.02% | 0.93% | 1.56% | 7.74% |
Catalyst Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 4 analysts is $98.78M, with a low forecast of $98.78M, and a high forecast of $98.78M. CPRX's average Quarter revenue forecast represents a -10.67% decrease compared to the company's last Quarter revenue of $110.57M (Dec 23).
Catalyst Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 6 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | $24.74M | $-37.19M | $46.70M | $42.14M | $30.80M | $25.66M | $28.61M | $17.40M | $12.85M | $14.10M | $15.93M | $9.98M | $8.76M | $11.83M | $11.08M | $11.45M | $9.08M | $14.64M | $11.87M | $-287.49K |
| Avg Forecast | $51.78M | $49.10M | $48.68M | $44.25M | $46.07M | $42.54M | $38.52M | $34.04M | $36.51M | $34.59M | $31.61M | $28.13M | $20.02M | $19.40M | $17.78M | $19.99M | $13.80M | $12.50M | $11.38M | $12.20M | $10.88M | $11.38M | $10.65M | $9.88M | $10.62M | $11.99M | $6.68M | $-1.09M |
| High Forecast | $53.87M | $51.08M | $50.64M | $47.22M | $47.15M | $42.54M | $38.52M | $34.04M | $37.07M | $34.60M | $32.89M | $29.27M | $20.83M | $19.40M | $17.78M | $23.99M | $13.80M | $12.50M | $11.38M | $14.64M | $10.88M | $11.38M | $10.65M | $11.85M | $10.62M | $11.99M | $6.68M | $-873.35K |
| Low Forecast | $49.66M | $47.08M | $46.68M | $42.45M | $44.56M | $42.53M | $38.52M | $34.04M | $36.17M | $34.59M | $30.31M | $26.98M | $19.20M | $19.40M | $17.78M | $15.99M | $13.80M | $12.50M | $11.38M | $9.76M | $10.88M | $11.38M | $10.65M | $7.90M | $10.62M | $11.99M | $6.68M | $-1.31M |
| Surprise % | - | - | - | - | - | - | - | - | 0.68% | -1.07% | 1.48% | 1.50% | 1.54% | 1.32% | 1.61% | 0.87% | 0.93% | 1.13% | 1.40% | 0.82% | 0.80% | 1.04% | 1.04% | 1.16% | 0.85% | 1.22% | 1.78% | 0.26% |
4 analysts predict CPRX's average Quarter EBITDA for Mar 24 to be $34.04M, with a high of $34.04M and a low of $34.04M. This is 37.60% upper than Catalyst Pharmaceuticals's previous annual EBITDA (Dec 23) of $24.74M.
Catalyst Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 6 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | $34.84M | $-30.76M | $37.76M | $29.57M | $25.47M | $22.75M | $21.62M | $13.24M | $9.31M | $10.33M | $12.18M | $7.66M | $11.44M | $43.34M | $9.78M | $10.43M | $7.93M | $13.63M | $10.96M | $-644.50K |
| Avg Forecast | $52.25M | $45.56M | $45.15M | $36.79M | $40.13M | $38.12M | $28.59M | $24.87M | $33.23M | $-37.62M | $31.85M | $40.38M | $26.34M | $23.68M | $21.19M | $15.13M | $14.46M | $12.96M | $11.97M | $9.37M | $11.22M | $11.97M | $10.60M | $9.27M | $12.88M | $13.71M | $3.12M | $-1.12M |
| High Forecast | $54.99M | $47.95M | $47.51M | $39.04M | $43.28M | $40.12M | $30.09M | $24.89M | $35.31M | $-35.61M | $33.52M | $42.50M | $27.72M | $23.68M | $21.19M | $18.16M | $14.46M | $12.96M | $11.97M | $11.24M | $11.22M | $11.97M | $10.60M | $11.12M | $12.88M | $13.71M | $3.12M | $-892.39K |
| Low Forecast | $49.47M | $43.13M | $42.74M | $34.53M | $36.20M | $36.09M | $27.07M | $24.85M | $29.77M | $-39.59M | $30.15M | $38.23M | $24.93M | $23.68M | $21.19M | $12.11M | $14.46M | $12.96M | $11.97M | $7.49M | $11.22M | $11.97M | $10.60M | $7.41M | $12.88M | $13.71M | $3.12M | $-1.34M |
| Surprise % | - | - | - | - | - | - | - | - | 1.05% | 0.82% | 1.19% | 0.73% | 0.97% | 0.96% | 1.02% | 0.88% | 0.64% | 0.80% | 1.02% | 0.82% | 1.02% | 3.62% | 0.92% | 1.13% | 0.62% | 0.99% | 3.52% | 0.58% |
Catalyst Pharmaceuticals's average Quarter net income forecast for Mar 24 is $24.87M, with a range of $24.85M to $24.89M. CPRX's average Quarter net income forecast represents a -28.62% decrease compared to the company's last Quarter net income of $34.84M (Dec 23).
Catalyst Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 6 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | $42.04M | $33.56M | $28.40M | $29.72M | $14.67M | $14.17M | $12.92M | $16.43M | $13.23M | $12.15M | $11.53M | $12.72M | $13.35M | $9.98M | $10.83M | $10.06M | $11.41M | $8.07M | $8.99M | $8.42M |
| Avg Forecast | $50.83M | $48.20M | $47.79M | $43.44M | $45.23M | $41.76M | $37.82M | $33.42M | $35.84M | $33.96M | $31.03M | $27.62M | $19.66M | $18.17M | $16.65M | $18.78M | $12.92M | $11.70M | $10.66M | $15.54M | $10.19M | $10.66M | $9.98M | $8.94M | $9.95M | $11.23M | $6.25M | $544.50K |
| High Forecast | $52.88M | $50.14M | $49.71M | $46.36M | $46.28M | $41.76M | $37.82M | $33.42M | $36.39M | $33.96M | $32.28M | $28.73M | $20.45M | $18.17M | $16.65M | $22.53M | $12.92M | $11.70M | $10.66M | $18.65M | $10.19M | $10.66M | $9.98M | $10.73M | $9.95M | $11.23M | $6.25M | $544.50K |
| Low Forecast | $48.75M | $46.22M | $45.83M | $41.67M | $43.75M | $41.75M | $37.82M | $33.42M | $35.51M | $33.96M | $29.76M | $26.48M | $18.85M | $18.17M | $16.65M | $15.02M | $12.92M | $11.70M | $10.66M | $12.43M | $10.19M | $10.66M | $9.98M | $7.16M | $9.95M | $11.23M | $6.25M | $544.50K |
| Surprise % | - | - | - | - | - | - | - | - | 1.17% | 0.99% | 0.92% | 1.08% | 0.75% | 0.78% | 0.78% | 0.88% | 1.02% | 1.04% | 1.08% | 0.82% | 1.31% | 0.94% | 1.09% | 1.13% | 1.15% | 0.72% | 1.44% | 15.46% |
Catalyst Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $33.42M, based on 4 Wall Street analysts, with a range of $33.42M to $33.42M. The forecast indicates a -20.49% fall compared to CPRX last annual SG&A of $42.04M (Dec 23).
Catalyst Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 6 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.29 | $0.36 | $0.28 | $0.24 | $0.22 | $0.21 | $0.13 | $0.09 | $0.10 | $0.12 | $0.07 | $0.11 | $0.42 | $0.09 | $0.10 | $0.08 | $0.13 | $0.11 | $-0.01 |
| Avg Forecast | $0.42 | $0.36 | $0.36 | $0.29 | $0.32 | $0.30 | $0.23 | $0.20 | $0.27 | $-0.30 | $0.25 | $0.32 | $0.21 | $0.19 | $0.17 | $0.14 | $0.12 | $0.10 | $0.10 | $0.09 | $0.09 | $0.10 | $0.09 | $0.09 | $0.10 | $0.11 | $0.03 | $-0.13 |
| High Forecast | $0.44 | $0.38 | $0.38 | $0.31 | $0.35 | $0.32 | $0.24 | $0.20 | $0.28 | $-0.28 | $0.27 | $0.34 | $0.22 | $0.19 | $0.17 | $0.14 | $0.12 | $0.10 | $0.10 | $0.09 | $0.09 | $0.10 | $0.09 | $0.09 | $0.10 | $0.11 | $0.03 | $-0.13 |
| Low Forecast | $0.39 | $0.34 | $0.34 | $0.28 | $0.29 | $0.29 | $0.22 | $0.20 | $0.24 | $-0.32 | $0.24 | $0.30 | $0.20 | $0.19 | $0.17 | $0.14 | $0.12 | $0.10 | $0.10 | $0.09 | $0.09 | $0.10 | $0.09 | $0.09 | $0.10 | $0.11 | $0.03 | $-0.13 |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | 0.97% | 1.42% | 0.87% | 1.14% | 1.16% | 1.24% | 0.96% | 0.78% | 0.96% | 1.25% | 0.81% | 1.22% | 4.38% | 1.06% | 1.15% | 0.77% | 1.18% | 4.40% | 0.08% |
According to 4 Wall Street analysts, Catalyst Pharmaceuticals's projected average Quarter EPS for Mar 24 is $0.20, with a low estimate of $0.20 and a high estimate of $0.20. This represents a 66010.00% increase compared to CPRX previous annual EPS of - (Dec 23).
Catalyst Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.69 | $70.00 | 10044.93% | Buy |
| BTAI | BioXcel Therapeutics | $0.60 | $12.00 | 1900.00% | Buy |
| XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
| INZY | Inozyme Pharma | $2.81 | $14.67 | 422.06% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.52 | $38.80 | 186.98% | Buy |
| TERN | Terns Pharmaceuticals | $5.91 | $14.25 | 141.12% | Buy |
| VKTX | Viking Therapeutics | $51.51 | $102.40 | 98.80% | Buy |
| MREO | Mereo BioPharma Group | $3.49 | $6.75 | 93.41% | Buy |
| ACAD | ACADIA Pharmaceuticals | $16.21 | $26.57 | 63.91% | Buy |
| SRPT | Sarepta Therapeutics | $106.62 | $169.06 | 58.56% | Buy |
| AKRO | Akero Therapeutics | $31.03 | $46.00 | 48.24% | Buy |
| AXSM | Axsome Therapeutics | $95.46 | $122.42 | 28.24% | Buy |
| INCY | Incyte | $70.56 | $84.56 | 19.84% | Buy |
| MDGL | Madrigal Pharmaceuticals | $314.17 | $315.75 | 0.50% | Buy |
| TGTX | TG Therapeutics | $30.32 | $27.60 | -8.97% | Buy |
| CPRX | Catalyst Pharmaceuticals | $21.39 | $19.38 | -9.40% | Buy |
| EXEL | Exelixis | $34.41 | $30.50 | -11.36% | Buy |